IL162835A0 - Human monoclonal antibodies against cd30 - Google Patents

Human monoclonal antibodies against cd30

Info

Publication number
IL162835A0
IL162835A0 IL16283503A IL16283503A IL162835A0 IL 162835 A0 IL162835 A0 IL 162835A0 IL 16283503 A IL16283503 A IL 16283503A IL 16283503 A IL16283503 A IL 16283503A IL 162835 A0 IL162835 A0 IL 162835A0
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
antibodies against
human monoclonal
human
monoclonal
Prior art date
Application number
IL16283503A
Other languages
English (en)
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of IL162835A0 publication Critical patent/IL162835A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
IL16283503A 2002-01-09 2003-01-07 Human monoclonal antibodies against cd30 IL162835A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34764902P 2002-01-09 2002-01-09
US40442702P 2002-08-19 2002-08-19
US43168402P 2002-12-06 2002-12-06
PCT/US2003/000440 WO2003059282A2 (en) 2002-01-09 2003-01-07 Human monoclonal antibodies against cd30

Publications (1)

Publication Number Publication Date
IL162835A0 true IL162835A0 (en) 2005-11-20

Family

ID=27407789

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16283503A IL162835A0 (en) 2002-01-09 2003-01-07 Human monoclonal antibodies against cd30
IL162835A IL162835A (en) 2002-01-09 2004-07-01 Human monoclonal antibodies against cd30
IL200604A IL200604A0 (en) 2002-01-09 2009-08-27 Human monoclonal antibodies against cd30

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL162835A IL162835A (en) 2002-01-09 2004-07-01 Human monoclonal antibodies against cd30
IL200604A IL200604A0 (en) 2002-01-09 2009-08-27 Human monoclonal antibodies against cd30

Country Status (13)

Country Link
US (2) US7387776B2 (xx)
EP (1) EP1471938A4 (xx)
JP (1) JP4562395B2 (xx)
KR (2) KR100668538B1 (xx)
CN (2) CN1638800A (xx)
AU (1) AU2003205055C1 (xx)
BR (1) BR0306808A (xx)
CA (1) CA2471702C (xx)
IL (3) IL162835A0 (xx)
MX (1) MXPA04006490A (xx)
NZ (1) NZ534174A (xx)
WO (1) WO2003059282A2 (xx)
ZA (1) ZA200405330B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CN1638800A (zh) 2002-01-09 2005-07-13 米德列斯公司 抗cd30的人类单克隆抗体
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
MX2007003533A (es) * 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008530244A (ja) 2005-02-18 2008-08-07 メダレックス， インク． フコシル残基を欠くｃｄ３０に対するモノクローナル抗体
US20090214544A1 (en) * 2005-04-25 2009-08-27 Medarex Method of treating cd30 positive lymphomas
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US8343928B2 (en) 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
HUE057936T2 (hu) 2005-07-18 2022-06-28 Seagen Inc Béta-glükuronid-linker-hatóanyag konjugátumok
JP4860703B2 (ja) * 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
EP1976883B1 (en) * 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
SI2235059T1 (sl) 2007-12-26 2015-06-30 Xencor, Inc. Fc variante s spremenjeno vezjo na fcrn
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
JP6126991B2 (ja) * 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
EP2707031B1 (en) 2011-05-08 2019-06-26 LegoChem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
EP2812702B1 (en) * 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
PE20141791A1 (es) 2012-02-13 2014-11-19 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos
MX356698B (es) 2013-02-14 2018-06-11 Bristol Myers Squibb Co Compuestos de tubulisina, metodos para obtenerlos y uso.
PL3677591T3 (pl) 2013-04-29 2023-06-26 Teva Pharmaceuticals Australia Pty Ltd Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2014306592B2 (en) 2013-08-14 2019-04-04 Bristol-Myers Squibb Company Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
PT3303373T (pt) 2015-05-30 2020-07-14 Molecular Templates Inc Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas
US10815301B2 (en) 2015-10-15 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-CD30 chimeric antigen receptors
CA3008678A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
JP2019518013A (ja) 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定性が向上したツブリシン類似体の抗体薬物結合体
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
JP7023933B2 (ja) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
JP7022328B2 (ja) 2017-03-30 2022-02-18 日油株式会社 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体
US11419946B2 (en) 2017-03-30 2022-08-23 Nof Corporation Heterobifunctional monodispersed polyethylene glycol and conjugate using same
KR20200013241A (ko) 2017-05-25 2020-02-06 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
KR102542988B1 (ko) 2018-03-13 2023-06-13 니치유 가부시키가이샤 주쇄 및 측쇄에 단분산 폴리에틸렌 글리콜을 가지는 헤테로이관능성 화합물
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
CN108441482A (zh) * 2018-05-21 2018-08-24 江苏省肿瘤医院 抗cd30的单克隆抗体、其杂交瘤细胞株、制备方法及应用
IL312163A (en) 2018-05-29 2024-06-01 Bristol Myers Squibb Co Modified atom groups that sacrifice themselves for use in prodrugs and conjugates and methods of use and preparation
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020068774A1 (en) * 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
WO2020068764A1 (en) * 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
SI3886914T1 (sl) 2018-11-30 2023-06-30 Bristol-Myers Squibb Company Protitelo, ki vsebuje C-terminalni podaljšek lahke verige, ki vsebuje glutamin, njegove konjugate ter metode in uporabe
CN113544155A (zh) 2018-12-12 2021-10-22 百时美施贵宝公司 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
WO2020135426A1 (zh) * 2018-12-24 2020-07-02 信达生物制药(苏州)有限公司 全人源的抗cd30单链抗体及其应用
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
WO2021060439A1 (ja) 2019-09-26 2021-04-01 日油株式会社 ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
CA3180613A1 (en) 2020-06-05 2021-12-09 Aung MYO Treatment of cd30-positive cancer
US20230364146A1 (en) 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
TW202237826A (zh) 2020-11-30 2022-10-01 瑞士商克里斯珀醫療股份公司 基因編輯的自然殺手細胞
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CA3218235A1 (en) 2021-04-27 2022-11-03 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors
WO2022269393A1 (en) 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
TW202330610A (zh) 2021-10-08 2023-08-01 丹麥商珍美寶股份有限公司 結合至ｃｄ３０及ｃｄ３之抗體
WO2023072953A1 (en) 2021-10-26 2023-05-04 Tessa Therapeutics Ltd. Cell lines for producing a retroviral vector encoding a car
TW202328438A (zh) 2021-12-08 2023-07-16 新加坡商泰莎治療有限公司 淋巴瘤之治療
CA3241438A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product
WO2023205148A1 (en) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2023233342A2 (en) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2024103000A1 (en) * 2022-11-11 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating vestibular schwannoma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
AU6909191A (en) 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
AU4953693A (en) 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
DE69605181T3 (de) * 1995-01-18 2006-08-24 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
WO1999040187A1 (de) 1998-02-06 1999-08-12 Hinrich Abken Nukleinsäuren zur modulation zellulärer aktivierung
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU2001285286A1 (en) 2000-08-29 2002-03-13 Noveon Ip Holdings Corp. Hydrogels containing substances
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
AU2002337935B2 (en) * 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CN1638800A (zh) * 2002-01-09 2005-07-13 米德列斯公司 抗cd30的人类单克隆抗体
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
CN102911987B (zh) * 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
JP2008530244A (ja) 2005-02-18 2008-08-07 メダレックス， インク． フコシル残基を欠くｃｄ３０に対するモノクローナル抗体

Also Published As

Publication number Publication date
CA2471702C (en) 2013-03-19
IL200604A0 (en) 2011-07-31
WO2003059282A3 (en) 2003-10-16
CA2471702A1 (en) 2003-07-24
CN1638800B (zh) 2014-07-16
KR20040075069A (ko) 2004-08-26
BR0306808A (pt) 2005-08-30
WO2003059282A2 (en) 2003-07-24
CN1638800A (zh) 2005-07-13
US20040006215A1 (en) 2004-01-08
AU2003205055B2 (en) 2007-05-10
EP1471938A2 (en) 2004-11-03
IL162835A (en) 2010-04-29
JP4562395B2 (ja) 2010-10-13
KR100829283B1 (ko) 2008-05-13
KR100668538B1 (ko) 2007-01-16
EP1471938A4 (en) 2008-03-05
AU2003205055A1 (en) 2003-07-30
US7387776B2 (en) 2008-06-17
MXPA04006490A (es) 2005-06-08
NZ534174A (en) 2007-03-30
ZA200405330B (en) 2006-05-31
AU2003205055C1 (en) 2009-04-23
US8088377B2 (en) 2012-01-03
US20100322920A1 (en) 2010-12-23
JP2005534281A (ja) 2005-11-17
KR20060108775A (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
IL200604A0 (en) Human monoclonal antibodies against cd30
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2003259294A8 (en) Humanized antibodies against human 4-1bb
IL168304A (en) Human monoclonal antibodies against cd25
EP1572131A4 (en) ANTIBODY THERAPY
IL165256A0 (en) Neutralizing human anti-igfr antibody
EP1633785A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
PL375405A1 (en) Antibodies
IL173273A0 (en) Modified human igf-1r antibodies
IL172511A0 (en) Specific human antibodies
AU2003277832A8 (en) Humanized tissue factor antibodies
AU2003287016A8 (en) Human sarcoma-associated antigens
GB0226878D0 (en) Antibodies
GB0325391D0 (en) Human monoclonal antibodies
GB0210508D0 (en) Antibodies
GB0218229D0 (en) Antibodies
GB0218230D0 (en) Antibodies
GB0218232D0 (en) Antibodies
HK1072381A1 (en) Cripto-specific antibodies cripto-specific
GB0218234D0 (en) Antibodies
GB0203018D0 (en) Antibodies
GB0218235D0 (en) Antibodies
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa